Join to View Full Profile
600 N Wolfe St# PathologBaltimore, MD 21287
Phone+1 410-614-1522
Fax+1 410-502-6736
Dr. Bhargava is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pavan Bhargava is a neurologist in Baltimore, MD and is affiliated with Johns Hopkins Hospital. He received his medical degree from Christian Medical College Vellore and has been in practice 12 years. He specializes in neuroimmunology/multiple sclerosis and neurophysiology and is experienced in multiple sclerosis.
Education & Training
Johns Hopkins UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 2013 - 2016
Southern Illinois UniversityResidency, Neurology, 2009 - 2013- Southern Illinois UniversityResidency, Internal Medicine, 2009 - 2010
Christian Medical College VelloreClass of 2005
Certifications & Licensure
MD State Medical License 2015 - 2026
IL State Medical License 2012 - 2017
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Start of enrollment: 2014 Nov 01
- A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis Start of enrollment: 2018 Jun 19
- Ocrelizumab Effects on the Metabolome in MS Start of enrollment: 2019 Jun 12
Publications & Presentations
PubMed
- Metabolic and lipid alterations in multiple sclerosis linked to disease severity.Rezvan Noroozi, Hui-Hsin Tsai, Ketian Yu, Paola Bronson, Karunakar Samuel
Multiple Sclerosis. 2025-04-01 - Accelerated Metabolomic Aging and Its Association with Social Determinants of Health in Multiple Sclerosis.Fatemeh Siavoshi, Rezvan Noroozi, Gina Chang, Vinicius A Schoeps, Matthew D Smith
Medrxiv. 2025-03-24 - Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.Dimitrios C Ladakis, Kimystian L Harrison, Matthew D Smith, Krista Solem, Sachin Gadani
Med. 2025-03-14
Press Mentions
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2nd, 2025- Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical TrialApril 2nd, 2025
- Key Updates in Disease-Modifying Therapies for RRMS from ACTRIMS 2025March 20th, 2025
- Join now to see all
Professional Memberships
- Fellow
External Links
- Lab websitehttp://bhargavalaboratory.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
